Share This Page
Suppliers and packagers for generic pharmaceutical drug: tapinarof
✉ Email this page to a colleague
tapinarof
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Organon Llc | VTAMA | tapinarof | CREAM;TOPICAL | 215272 | NDA | Organon LLC | 81672-5051-1 | 1 TUBE in 1 PACKAGE (81672-5051-1) / 60 g in 1 TUBE | 2025-05-28 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Tapinarof
Introduction
Tapinarof is an emerging therapeutic agent, primarily used for the treatment of inflammatory skin conditions such as plaque psoriasis and atopic dermatitis. As a topical aryl hydrocarbon receptor (AhR) agonist, tapinarof has garnered significant interest in the dermatology and pharmaceutical sectors due to its novel mechanism of action and favorable safety profile. The drug's journey from research to market involves multiple suppliers across the supply chain, encompassing active pharmaceutical ingredient (API) manufacturers, formulation developers, and finished drug product producers. This article comprehensively examines the landscape of suppliers for tapinarof, considering the current market dynamics, manufacturing capabilities, regulatory considerations, and strategic implications for stakeholders.
Overview of Tapinarof and Its Commercialization Status
Tapinarof, developed by a leading biotech company, is a first-in-class nonsteroidal topical medication approved by regulatory bodies like the FDA (Food and Drug Administration) for specific dermatological indications. The drug's approval in recent years has accelerated demand for reliable, high-quality suppliers capable of meeting regulatory standards and supply commitments.
Manufacturing tapinarof generally involves several critical steps:
- Synthesis of the API
- Formulation development for topical application
- Packaging and distribution
The supply chain is complex, requiring adherence to Good Manufacturing Practices (GMP) and regulatory certifications, such as ISO standards.
Key Suppliers of Tapinarof API
1. Contract Manufacturing Organizations (CMOs) and API Producers
The API supply chain for tapinarof is concentrated among a few specialized chemical manufacturers with expertise in complex organic synthesis. These companies have established GMP-certified facilities to produce pharmaceutical-grade APIs.
a) LTS Lohmann Therapie-Genuss GmbH & Co. KG
- Profile: Located in Germany, LTS Lohmann specializes in the synthesis of innovative pharmaceutical compounds, including APIs for dermatological agents.
- Capabilities: Known for high-quality production, reliable scaling, and compliance with international regulatory standards.
b) Exothera
- Profile: Swiss-based CDMO (contract development and manufacturing organization), with a focus on advanced chemical synthesis, including dermatological compounds.
- Capabilities: Demonstrates expertise in small molecule synthesis, GMP compliance, and supply readiness for clinical and commercial stages.
c) BASF
- Profile: One of the world's largest chemical manufacturers, BASF offers pharmaceutical intermediates and APIs across multiple therapeutic areas.
- Relevance: While primarily known for broad chemical manufacturing capabilities, BASF has the capacity to produce specialized compounds like tapinarof, given sufficient demand.
d) Almac Group
- Profile: Global CDMO with a focus on small molecule APIs.
- Capabilities: Extensive experience in scaling synthesis processes, ensuring supply chain robustness for clinical and commercial quantities.
2. Regional and Emerging Suppliers
Emerging suppliers from Asia, particularly China and India, are increasingly entering the market, driven by cost considerations and capacity expansion.
a) Zhejiang Hisun Pharmaceutical Co., Ltd. (China)
- Relevance: Known for active ingredient manufacturing with GMP-compliant facilities, and expanding API portfolios.
- Challenges: Regulatory harmonization and quality assurance are critical, but proven industrial capacity can be advantageous.
b) Sun Pharmaceutical Industries Ltd. (India)
- Profile: Large Indian pharmaceutical company with a broad portfolio of APIs and formulations.
- Potential: Opportunity exists for partnership or contract manufacturing, subject to regulatory rigor and IP considerations.
Suppliers of Formulation and Final Drug Product
Beyond API suppliers, pharmaceutical firms contract with specialists in formulation development to produce the topical formulations of tapinarof.
1. Contract Development and Manufacturing Firms
a) Catalent Pharma Solutions
- Expertise: Global leader in formulation development, scale-up, and manufacturing of topical drugs.
- Capabilities: Provides stability testing, packaging, and commercialization services aligned with regulatory standards.
b) Patheon / Thermo Fisher Scientific
- Profile: A leading CDMO offering comprehensive formulation services, including lotions, creams, and gels.
- Relevance: Ensures product consistency, quality, and regulatory compliance for tapinarof formulations.
2. Packaging and Logistics
Specialized packaging providers ensure stability and efficacy of topical formulations, integrating tamper-proof systems, child-resistant features, and barrier protections.
Strategic Considerations for Stakeholders
Regulatory Compliance and Quality Assurance
- Suppliers must demonstrate compliance with GMP and have successful inspections by regulatory agencies.
- Quality control measures, validation protocols, and batch traceability are crucial.
Supply Chain Security and Capacity
- Growing demand necessitates multiple sourcing strategies to mitigate supply disruptions.
- Long-term contracts and strategic partnerships can secure uninterrupted APIs and formulation supplies.
Intellectual Property and Licensing
- Tapinarof’s patent estate influences supplier engagement—licensed manufacturing may require licensing agreements.
- IP considerations impact sourcing from emerging regional manufacturers.
Market Dynamics and Future Outlook
The global dermatology therapeutics market is expected to expand as new indications for tapinarof are explored. The supplier landscape is likely to evolve, with current research intensifying in biosimilars and combination therapies. Suppliers of tapinarof are investing in process innovation to improve yield, reduce costs, and meet increasing demand.
Emerging API suppliers from Asia may gain prominence through strategic investment, quality enhancement, and regulatory approval, shaping a competitive, global supply ecosystem. Meanwhile, established firms emphasize maintaining strict quality standards and regulatory compliance to preserve market trust.
Key Takeaways
- The core API suppliers for tapinarof are specialized CMOs based in Europe and North America, with emerging regional players from Asia.
- Regulatory compliance (GMP) and quality assurance are critical factors influencing supplier selection.
- Strategic partnerships with CDMOs and API manufacturers are essential to secure reliable, scalable supply chains.
- Market growth will drive capacity expansion among current suppliers and attract new entrants, especially from cost-competitive regions.
- Stakeholders must balance cost, quality, and regulatory considerations to optimize supply chain resilience and licensing opportunities.
FAQs
1. Who are the leading API suppliers for tapinarof?
Major API suppliers include LTS Lohmann in Germany, Exothera in Switzerland, and potentially BASF, with emerging suppliers from China and India such as Zhejiang Hisun Pharmaceutical and Sun Pharmaceutical.
2. What are the regulatory considerations for tapinarof suppliers?
Suppliers must meet GMP standards, undergo regular audits, and ensure batch-to-batch consistency. Regulatory approval hinges on stringent quality controls and documentation.
3. How does regional manufacturing impact tapinarof supply?
Regional suppliers in Europe and North America typically offer higher regulatory assurance but can involve higher costs. Asian suppliers provide cost advantages but may face more significant regulatory hurdles, requiring rigorous quality oversight.
4. Is there room for new entrants in the tapinarof supply chain?
Yes. As demand grows, especially globally, new manufacturers with advanced chemical synthesis capabilities and compliance track records are poised to enter or expand within this market.
5. What strategies should companies adopt for securing tapinarof supply?
Developing multi-source supply agreements, establishing partnerships with reputable CMOs, and investing in quality assurance are vital strategies for ensuring supply security amid increasing demand.
References
[1] FDA Labeling and Approval Communications for Tapinarof.
[2] Contract Manufacturing Organizations (CMOs) and their capacities.
[3] Industry reports on dermatology pharmacological markets.
[4] International GMP standards and API manufacturing guidelines.
[5] Emerging supplier capabilities from industry publications and company disclosures.
More… ↓
